Skip to main content
Clinical Trials/NCT02092675
NCT02092675
Completed
Not Applicable

Endothelial Dysfunction and Frequent Exacerbator Phenotype in Patient With Chronic Obstructive Pulmonary Disease

Andrea Vukic Dugac1 site in 1 country117 target enrollmentMarch 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
Andrea Vukic Dugac
Enrollment
117
Locations
1
Primary Endpoint
difference in endothelial dysfunction
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to investigate the role of endothelial dysfunction in chronic obstructive pulmonary disease.

Detailed Description

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in developed countries. Acute exacerbations and cardiovascular diseases are the major causes of morbidity and mortality in COPD patients. According to the frequency of exacerbations, phenotype "frequent exacerbator" is defined and characterised with severe clinical course and was recognised as an increased risk for cardiovascular mortality. Recent studies considered that systemic inflammation plays a key role in the pathogenesis of COPD and endothelial dysfunction is a suspected link between increased cardiovascular mortality and systemic inflammation in COPD patients. Endothelial dysfunction is assessed by determining flow mediated dilatation index (FMD index) or plasma markers. Previous studies have suggested the presence of endothelial dysfunction in COPD patients, as well as the deterioration of endothelial function during exacerbations of COPD. This study will, for the first time, systematically explore endothelial dysfunction in two phenotypically distinct groups of COPD patients with simultaneous assessment of endothelial function flow mediated dilatation index (FMD index) and plasma markers.

Registry
clinicaltrials.gov
Start Date
March 2013
End Date
May 2014
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Andrea Vukic Dugac
Responsible Party
Sponsor Investigator
Principal Investigator

Andrea Vukic Dugac

pulmonary disease specialist

Clinical Hospital Centre Zagreb

Eligibility Criteria

Inclusion Criteria

  • COPD patients in stable condition ( without exacerbation min 1 months ago)
  • Over 40 years
  • History of at least 10 py

Exclusion Criteria

  • acute exacerbation of COPD
  • active malignancy
  • autoimmune disease
  • acute myocardial infarction
  • diabetes mellitus with late complications
  • congestive heart failure
  • women of childbearing potential

Outcomes

Primary Outcomes

difference in endothelial dysfunction

Time Frame: 6 months

Evidence of difference in endothelial dysfunction between COPD frequent exacerbator phenotype group and COPD non frequent exacerbator phenotype group

Secondary Outcomes

  • difference in pulmonary functional tests(6 months)

Study Sites (1)

Loading locations...

Similar Trials